,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-05-10 08:07:00,Teva Pharmaceutical Industries' ( TEVA ) first quarter earnings of $1.47 per American Depositary Share (ADS) were 3 cents above the Zacks Consensus Estimate and 41% above the year-ago earnings.,0.8187355399131775,0.1509263515472412,0.030338145792484283,positive,0.6678091883659363
1,2012-05-10 08:07:00,"First quarter revenues increased 25% to $5.1 billion, missing the Zacks Consensus Estimate of $5.6 billion.",0.8395955562591553,0.12590879201889038,0.03449571132659912,positive,0.7136867642402649
2,2012-05-10 08:07:00,"The company said that it is working on streamlining some of its commercial arrangements in the U.S., which are expected to benefit the company in the near and mid-term.",0.6871190667152405,0.01092611625790596,0.30195486545562744,positive,0.6761929392814636
3,2012-05-10 08:07:00,The company is renegotiating certain distribution service agreements in the U.S. so as to establish a new fee structure.,0.7425075173377991,0.012417986057698727,0.24507451057434082,positive,0.730089545249939
4,2012-05-10 08:07:00,"However, Teva reported that the implementation of these changes negatively impacted first quarter 2012 revenues by $180 million.",0.017670350149273872,0.9595395922660828,0.02279001474380493,negative,-0.9418692588806152
5,2012-05-10 08:07:00,The company reported sales growth in RoW (21%) and the U.S. (46%).,0.8540557622909546,0.012493216432631016,0.13345108926296234,positive,0.8415625691413879
6,2012-05-10 08:07:00,"Revenues, however, declined in Europe (down 2%).",0.01711444929242134,0.9718788266181946,0.011006754823029041,negative,-0.9547643661499023
7,2012-05-10 08:07:00,Currency fluctuations negatively impacted total revenues by $81 million.,0.016910908743739128,0.9673157930374146,0.015773363411426544,negative,-0.9504048824310303
8,2012-05-10 08:07:00,Teva expects foreign currencies to continue to negatively impact 2012 sales by about $650 - $700 million.,0.019792821258306503,0.9547539949417114,0.025453126057982445,negative,-0.934961199760437
9,2012-05-10 08:07:00,"Sales in the U.S. grew 46% to $2.8 billion in the reported quarter, boosted by the inclusion of Cephalon and the strong performance of branded and generic products.",0.9560487866401672,0.01661202684044838,0.027339190244674683,positive,0.9394367337226868
10,2012-05-10 08:07:00,The company launched seven new products in the first quarter of 2012.,0.21224240958690643,0.0057330685667693615,0.7820245027542114,neutral,0.20650933682918549
11,2012-05-10 08:07:00,U.S. generic sales rebounded with sales increasing 29% to $1.2 billion.,0.9549815058708191,0.021113164722919464,0.023905333131551743,positive,0.9338683485984802
12,2012-05-10 08:07:00,Sales benefited from the launch of several new products including the exclusive generic launch of Eli Lilly's ( LLY ) Zyprexa.,0.9137228727340698,0.013123245909810066,0.07315394282341003,positive,0.9005995988845825
13,2012-05-10 08:07:00,Teva has partnered with Dr. Reddy's Laboratories ( RDY ) for Zyprexa.,0.8091526031494141,0.01087531354278326,0.17997203767299652,positive,0.7982773184776306
14,2012-05-10 08:07:00,Another important product launch was that of a generic version of Pfizer's ( PFE ) Lipitor.,0.6307563781738281,0.010656836442649364,0.358586847782135,positive,0.6200995445251465
15,2012-05-10 08:07:00,Teva has an agreement with Ranbaxy regarding generic Lipitor.,0.6434983015060425,0.01450998242944479,0.34199175238609314,positive,0.6289883255958557
16,2012-05-10 08:07:00,The performance of the U.S. generics segment should continue improving.,0.9401946067810059,0.014374903403222561,0.04543042555451393,positive,0.9258196949958801
17,2012-05-10 08:07:00,Branded product revenues increased 54% to $2.1 billion in the first quarter of 2012.,0.9453296661376953,0.01397863682359457,0.04069159924983978,positive,0.9313510060310364
18,2012-05-10 08:07:00,"Revenues benefited from the inclusion of Cephalon products - Provigil ($291 million), Treanda ($148 million) and Nuvigil ($84 million).",0.6684153079986572,0.009567542001605034,0.3220171332359314,positive,0.6588477492332458
19,2012-05-10 08:07:00,"Key branded product Copaxone posted global in-market sales of $941 billion, up 4%.",0.9506791234016418,0.026589950546622276,0.022730838507413864,positive,0.9240891933441162
20,2012-05-10 08:07:00,"Other products/segments that contributed to growth were Azilect at $96 million, up 7%, the global respiratory business ($190 million, up 4%), and the women's health business ($108 million, up 5%).",0.8063451647758484,0.014084074646234512,0.1795707494020462,positive,0.7922610640525818
21,2012-05-10 08:07:00,Revenues in Europe declined 2% to $1.3 billion.,0.016407029703259468,0.9732815027236938,0.01031158585101366,negative,-0.9568744897842407
22,2012-05-10 08:07:00,"Although revenues were positively impacted by the inclusion of Cephalon products and the strong performance of branded products especially Copaxone, generic sales were impacted by the macro-economic conditions and healthcare reforms in key European markets.",0.6807010173797607,0.15671810507774353,0.1625809371471405,positive,0.5239828824996948
23,2012-05-10 08:07:00,European generic revenues declined 15% to $775 million.,0.016128838062286377,0.9726990461349487,0.011172173544764519,negative,-0.9565702080726624
24,2012-05-10 08:07:00,"RoW (Rest of the World including Canada, Israel, certain markets in Eastern Europe, Latin America and Asia) revenues grew 21% during the quarter with sales coming in at $1 billion.",0.9547163844108582,0.017955860123038292,0.02732778899371624,positive,0.9367605447769165
25,2012-05-10 08:07:00,"Increased sales in Eastern Europe, Latin America and Israel helped boost revenues.",0.9504950046539307,0.02492314577102661,0.02458184026181698,positive,0.925571858882904
26,2012-05-10 08:07:00,"Moreover, sales benefited from the Taiyo and Cephalon acquisitions.",0.937346875667572,0.014643545262515545,0.048009563237428665,positive,0.9227033257484436
27,2012-05-10 08:07:00,API sales increased 8% to $199 million.,0.9524191617965698,0.016579678282141685,0.0310011375695467,positive,0.9358394742012024
28,2012-05-10 08:07:00,OTC revenues increased 7% to $196 million.,0.9558612704277039,0.017888562753796577,0.02625022456049919,positive,0.9379727244377136
29,2012-05-10 08:07:00,Teva has a partnership agreement with Procter & Gamble ( PG ) targeting the consumer health care market.,0.8179993033409119,0.011319614015519619,0.17068113386631012,positive,0.8066796660423279
30,2012-05-10 08:07:00,Research & Development expense increased to $292 million from $239 million in the year-ago period.,0.6440717577934265,0.3342019319534302,0.021726325154304504,positive,0.30986982583999634
31,2012-05-10 08:07:00,The inclusion of Cephalon was the main reason for the increase.,0.26182883977890015,0.00782641489058733,0.7303447127342224,neutral,0.2540024220943451
32,2012-05-10 08:07:00,"Meanwhile, Selling and Marketing (S&M) expenditure increased to $916 million from $825 million mainly due to the inclusion of Cephalon, Taiyo and Theramex.",0.9590326547622681,0.021159663796424866,0.019807731732726097,positive,0.9378730058670044
33,2012-05-10 08:07:00,The company repurchased 11.9 million shares during the quarter.,0.1476573944091797,0.008348244242370129,0.8439943790435791,neutral,0.13930915296077728
34,2012-05-10 08:07:00,Teva has a $3 billion share buyback program which was announced in Dec 2011.,0.4378228485584259,0.007326717954128981,0.5548503994941711,neutral,0.43049612641334534
35,2012-05-10 08:07:00,We are positive on this program which will return value to shareholders.,0.8854689598083496,0.012128298170864582,0.1024027168750763,positive,0.8733406662940979
36,2012-05-10 08:07:00,The company refrained from providing an outlook on 2012 and did not reaffirm its previously issued 2012 guidance.,0.038417182862758636,0.16906434297561646,0.7925184369087219,neutral,-0.13064715266227722
37,2012-05-10 08:07:00,"The new CEO, Dr. Jeremy Levin, intends to review the business before giving any guidance or insight on future plans for the company.",0.027821818366646767,0.005945008248090744,0.9662331342697144,neutral,0.021876810118556023
38,2012-05-10 08:07:00,We expect an update later this year.,0.03911202400922775,0.0052684904076159,0.9556194543838501,neutral,0.03384353220462799
39,2012-05-10 08:07:00,The Zacks Consensus Estimate for 2012 currently stands at $5.61 per share.,0.03326980769634247,0.013099350966513157,0.9536308646202087,neutral,0.020170457661151886
40,2012-05-10 08:07:00,"We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term 'Hold' rating).",0.04198456183075905,0.12792539596557617,0.8300900459289551,neutral,-0.08594083786010742
41,2012-05-10 08:07:00,"Although the company's first quarter earnings exceeded expectations, revenues were short of expectations.",0.04803046956658363,0.9220342040061951,0.02993539534509182,negative,-0.8740037083625793
42,2012-05-10 08:07:00,"Moreover, the lack of visibility regarding 2012 outlook is disappointing.",0.020220445469021797,0.9267781972885132,0.053001243621110916,negative,-0.9065577387809753
43,2012-05-10 08:07:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
44,2012-05-10 08:07:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
